ClinicalTrials.gg
Active, not recruitingNCT06385288Updated Oct 13, 2026

Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas

An interventional study of Blood and tissue collection for immunological studies, advanced imaging. and neoadjuvant Therapy in Soft Tissue Sarcoma Adult, sponsored by University Hospital Tuebingen. Active, not recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by University Hospital Tuebingen · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled Jul 2021, registered Nov 2023).
Updated Oct 13, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 103 studies in Sarcoma with a site in Germany — 21 open to participants now, 30 under way, 3 of them phase 3. Sarcoma · Germany.

Planned enrollment
66th of 83
30 · median 103
Started
2021
with 5 others
No phase
12 of 103
5 open now
Primary completion
2028-12
later than 23 of 29 live
Registered
92nd of 103
by date
Lead sponsor
6 of 103
University Hospital Tuebingen

Among the 103 studies in Sarcoma with a site in Germany, this one is the 66th largest by planned enrollment of the 83 interventional ones that give a count, is one of 6 that started in 2021, is one of 12 with no phase, reaches primary completion later than 23 of the 29 other live ones, and was the 92nd registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

21 of the 103 studies in Sarcoma with a site in Germany are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 103 studies in Sarcoma with a site in Germany, or all of them as a file.
02

Study summary

"Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcoma" is a prospective study with additional translational research using preoperative and postoperative tissue, blood sampling and advanced imaging.

Read the detailed description

All patients (> 18 Years) with histologically confirmed high-risk soft tissue sarcoma eligible for neoadjuvant multimodal therapy (including radiotherapy +/- concomitant and sequential chemotherapy +/- hyperthermia as well as surgery) are screened for the study. Neoadjuvant therapy consists of 50-50.4 Gy in 25-28 fractions. Additional concomitant or sequential chemotherapy may be applied in selected cases (young patients, high-grade tumors). Additional hyperthermia concomitant to neoadjuvant radiotherapy is applied in selected cases if not contraindicated.

Preoperative tissue sampling to generate primary tumor cell lines in additional translational research is performed in each patient with a lesion suspect for soft tissue sarcoma and eligible for multimodal therapy. Primary cell lines are analyzed biologically (growth pattern, radioresistance, migration, molecular markers RT-PCR, immunological properties such as immunogenic cell death, lysis by cellular immunotherapies such as CAR-NK cells. Postoperative tumor tissues are additionally analyzed for immune cell mapping using complex immunohistochemistry. Biopsy and resection should include proteome analysis and DNA sequencing (only of the tumor tissue, not normal tissue).

Additional immunological monitoring (including cellular immune status, serum marker e.g. cell free DNA, HMGB1) is performed using blood sampling with in total 4 blood controls (25 ml each, before neoadjuvant radiotherapy, during the second and last week of radiotherapy as well as before surgery). In patients treated with concomitant MR-guided hyperthermia, weekly MR-imagine is performed.

Follow-up is carried out as part of the oncological controls over 5 years. The overall study is planned over a period of 5 years (interventional part), additional 5 years follow-up period.

03

Conditions studied

  • Soft Tissue Sarcoma Adult

Browse trials for

Keywords

  • Soft tissue sarcomas
  • immunological examinations
  • neoadjuvant therapy
  • radiotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Planned histological confirmation for especially high-risk soft tissue sarcoma via open Sampling
  • Indication for multimodal therapy (radiation and locoregional Hyperthermia, optionally with simultaneous chemotherapy)
  • Planned resection of a department of the CWS
  • Age > 18 years
  • Ability to consent
  • Additionally for imaging study: Treatment on the combined MR hyperthermia device

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years
  • Poor understanding (language etc.)
  • Lack of reconnaissance ability
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Single-arm trial

    Blood and tissue collection for immunological studies under neoadjuvant Therapy of soft tissue sarcomas. Prospective data collection and translational accompanying research on standard therapy. Use of tissue, blood samples and advanced imaging.

    Other: Blood and tissue collection for immunological studies, advanced imaging. · Other: neoadjuvant Therapy

Interventions

  • OtherBlood and tissue collection for immunological studies, advanced imaging.

    Blood and tissue collection for immunological studies under neoadjuvant Therapy of soft tissue sarcomas. Prospective data collection and translational accompanying research on standard therapy. Use of tissue, blood samples and advanced imaging.

  • Otherneoadjuvant Therapy

    neoadjuvant Therapy

06

What researchers measure

Primary outcomes

  1. Description of the cellular immune status via flow-cytometrie from collected blood samples

    Blood samples are taken on the days of simulation-CT, first and third week of the radiation therapy, as well as before surgery.

    Time frame: 5 years of recruitment, 5 years follow-up

  2. Description of the cellular immune status on tissue samples ussing komplex immunohistochemie

    Tissue samples are taken as incisional biopsie as well as in the tumor tissue after the surgery

    Time frame: 5 years of recruitment, 5 years follow-up

  3. Measurement of the cellular free DNA from collected blood samples

    Blood samples are taken on the days of simulation-CT, first and third week of the radiation therapy, as well as before surgery.

    Time frame: 5 years of recruitment, 5 years follow-up

  4. Measurement of HMGB1 from collected blood samples

    Blood samples are taken on the days of simulation-CT, first and third week of the radiation therapy, as well as before surgery.

    Time frame: 5 years of recruitment, 5 years follow-up

  5. Evaluation of morphological tumor characteristics (size, diffusion) with weekly MRIs

    Weekly MRIs during neoadjuvant radiation therapy

    Time frame: 5 years of recruitment, 5 years follow-up

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Dec 2028, 89 months after the start.

Of 145 non-industry interventional studies with no phase under Sarcoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 120. This study's planned 89 months is above that.

Counting every sponsor, half of 148 studies reached it within 59 months; a quarter within 34 and three quarters within 120.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Jul 2026 → Dec 2028 and completion Jul 2031 → Dec 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2023
First posted
Apr 26, 2024
StartActual
Jul 21, 2021
Primary completionEst.
Dec 31, 2028was Jul 2026
CompletionEst.
Dec 31, 2028was Jul 2031
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 13, 2026
Sites
1 site added, 1 site removed
Show site
  • University Hospital Tuebingen · Tübingen, Germany
Show 1 removed
  • University Hospital Tuebingen · Tübingen, Germany
Oct 13, 2026
Primary completion
Jul 21, 2026→Dec 31, 2028
Oct 13, 2026
Study completion
Jul 21, 2031→Dec 31, 2028
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • University Hospital Tuebingen · Tübingen, Germany
    Show 1 removed
    • University Hospital Tuebingen · Tübingen, Germany
    Primary completion Jul 21, 2026→Dec 31, 2028
    Study completion Jul 21, 2031→Dec 31, 2028
    + 4 other changes: index terms, verification date, oversight details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06385288
Responsible party
Sponsor
First posted
Apr 26, 2024
Start date
Jul 21, 2021
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion